Comparison · NCT02899156-e5693633
Flumazenil Group vs Placebo Group: Number of Participants With Delirium Resolution
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Flumazenil Group vs Placebo Group: Number of Participants With Delirium Resolution. Trial comparisons, record NCT02899156-e5693633. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02899156-e5693633
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.9 | 0.596 | 0.982 | wilson | |
| Risk in group 2 | 0.7 | 0.397 | 0.892 | wilson | |
| Risk difference, group 1 minus group 2 | 0.2 | -0.16 | 0.514 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.29 | 0.815 | 2.03 | log | |
| Odds ratio, group 1 over group 2 | 3.86 | 0.326 | 45.6 | log | |
| Number needed to treat, for one more participant with the outcome on Flumazenil Group than on Placebo Group | 5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Flumazenil Group | The flumazenil continuous infusion is started at an initial dose of 0.1 mg/hr., and can be titrated up to a maximum of 0.3 mg/hr. Dose titrations may occur every 60 minutes to maintain RASS scores of 0 to +1. The maximum rate is 0.3 mg/hr.~Flumazenil | 9 | 10 | OG000 |
| Group 2 | Placebo Group | The placebo continuous infusion is started at an initial dose of 0.1 mg/hr (2 ml/hr)., and can be titrated up to a maximum of 0.3 mg/hr. Dose titrations may occur every 60 minutes to maintain RASS scores of 0 to +1. The maximum rate is 0.3 mg/hr.~Placebo: 0.9% normal saline | 7 | 10 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Delirium Resolution
- Description
- defined by the proportion of patients who were delirium free at 14 days after randomization
- Time frame
- up to 14 days after randomization
- Population
Source ClinicalTrials.gov
Trial
- Title
- Flumazenil for Hypoactive Delirium Secondary to Benzodiazepine Exposure
- NCT number
- NCT02899156
- Phases
- PHASE4
- Conditions
- Hypoactive Delirium
- Interventions
- Flumazenil, Placebo
- Lead sponsor
- University of California, Davis
- Results first posted
- 2020-07-23
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02899156?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02899156-e5693633